C1orf21 Inhibitors
C1orf21 inhibitors are a diverse set of chemical compounds that suppress the functional activity of C1orf21 through various signaling pathways. Imatinib, for instance, targets tyrosine kinases which, when inhibited, may affect C1orf21's role in such signaling pathways by reducing the phosphorylation of downstream molecules, thereby decreasing C1orf21's activity. Similarly, Rapamycin and Wortmannin, as inhibitors of mTOR and PI3K respectively, diminish the signaling that is critical for protein synthesisand cellular proliferation which could indirectly reduce the functional activity of C1orf21 if it is under the control of these pathways. Trichostatin A, by affecting histone deacetylase, alters chromatin structure and can indirectly diminish C1orf21 activity by modifying the expression of genes that regulate its function. Moreover, LY 294002, PD 98059, and U0126, each targeting different components of the MAPK/ERK pathway, could lead to a decrease in C1orf21 activity by reducing the pathway's output, assuming C1orf21's function is regulated by these signaling routes.
In addition to these, compounds like W-7 and BAPTA/AM, which impede calcium-calmodulin signaling and sequester intracellular calcium, respectively, can also reduce C1orf21 activity by blocking calcium-dependent processes that might be crucial for C1orf21's role. SB 203580 and SP600125, both of which are inhibitors of specific MAP kinases (p38 and JNK, respectively), would contribute to the diminution of C1orf21 activity by interfering with stress and inflammatory signaling pathways. Lastly, Gefitinib, by inhibiting EGFR tyrosine kinase activity, could also play a role in downregulating C1orf21 if its activity is associated with EGFR-mediated signaling events. These inhibitors, through their targeted effects on various cellular signaling mechanisms, collectively contribute to the indirect inhibition of C1orf21 without affecting its expression or direct activation, thereby providing a comprehensive approach to diminishing its functional activity within cells.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets specific tyrosine kinases, which can indirectly lead to the inhibition of C1orf21 if C1orf21 is involved in tyrosine kinase signaling pathways. By inhibiting these kinases, imatinib would diminish the phosphorylation events that propagate signaling cascades, potentially suppressing the functional activity of C1orf21. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can reduce the activity of the mTOR pathway, which may play a role in the regulation of C1orf21. By inhibiting mTOR, rapamycin would diminish protein synthesis and other processes that are upregulated by mTOR signaling, indirectly decreasing C1orf21 functional activity if it is regulated by this pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor which could lead to changes in chromatin structure and gene expression profiles, potentially affecting C1orf21 if histone acetylation states influence its activity. This compound would diminish the expression of genes that need a condensed chromatin structure for their suppression, which may include regulators of C1orf21 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor that would decrease PI3K pathway signaling, reducing the levels of PIP3 and subsequent AKT activation. If C1orf21 activity is modulated by PI3K/AKT signaling, this inhibitor would indirectly reduce its functional activity by lowering the activity of this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a MEK inhibitor that indirectly could reduce the functional activity of C1orf21 by inhibiting the MAPK/ERK pathway. This would lead to diminished phosphorylation of ERK, affecting downstream signaling processes that might regulate C1orf21 activity. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
W-7 is a calmodulin antagonist. If C1orf21's activity is modulated by calcium-calmodulin dependent pathways, W-7 would indirectly inhibit C1orf21 by blocking the signaling events that are mediated by calmodulin. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor that would impede the p38 MAPK signaling pathway. If C1orf21 is regulated by stress-activated pathways, this inhibitor could diminish the functional activity of C1orf21 by interfering with this specific signaling route. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that would decrease PI3K pathway signaling, indirectly reducing the functional activity of C1orf21 if its activity is modulated by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that would block the JNK signaling pathway. If C1orf21 is involved in cellular responses mediated by JNK, this inhibitor would lead to a decrease in C1orf21 functional activity by dampening this pathway. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA/AM is an intracellular calcium chelator. By sequestering intracellular calcium, it would inhibit calcium-dependent signaling pathways. If C1orf21 requires calcium signaling for its activity, BAPTA-AM would lead to a functional inhibition of C1orf21. | ||||||